Literature DB >> 2771957

Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

H Ahuja1, M Bar-Eli, S H Advani, S Benchimol, M J Cline.   

Abstract

Molecular mechanisms responsible for the clinical progression of chronic myelocytic leukemia to its accelerated phase or to blast crisis have not been defined. We found alterations of the p53 gene (p53 is a 53-kDa nuclear protein) including deletions and rearrangements in 8 of 34 patients in blast crisis and 1 of 4 patients in the accelerated phase, but in only 1 of 38 patients in the chronic phase of chronic myelocytic leukemia. Only two other examples of p53 gene alterations were found among 203 patients with hematologic malignancies and solid tumors. Transcripts of the p53 gene were uniformly found in chronic-phase cells, but gene expression was variable in blast crisis, and transcripts were reduced or undetectable in 10 of 16 patients. Heterogeneous alterations in the structure and expression of the p53 gene appear to be relatively frequent in blast crisis and may be involved in the evolution of disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2771957      PMCID: PMC297930          DOI: 10.1073/pnas.86.17.6783

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Characterization of the human p53 gene.

Authors:  P Lamb; L Crawford
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

2.  Growth regulation of a cellular tumour antigen, p53, in nontransformed cells.

Authors:  N C Reich; A J Levine
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

3.  Increased expression of p53 protein in human leukemia cells.

Authors:  H P Koeffler; C Miller; M A Nicolson; J Ranyard; R A Bosselman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.

Authors:  E Harlow; N M Williamson; R Ralston; D M Helfman; T E Adams
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

5.  Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.

Authors:  S J Collins; I Kubonishi; I Miyoshi; M T Groudine
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

6.  Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation.

Authors:  J Yokota; Y Tsunetsugu-Yokota; H Battifora; C Le Fevre; M J Cline
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

7.  Genomic alterations involving the c-myc proto-oncogene locus during the evolution of a case of chronic granulocytic leukaemia.

Authors:  D M McCarthy; F V Rassool; J M Goldman; S V Graham; G D Birnie
Journal:  Lancet       Date:  1984-12-15       Impact factor: 79.321

8.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

Authors:  J B Konopka; S M Watanabe; O N Witte
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

9.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

Authors:  L F Parada; H Land; R A Weinberg; D Wolf; V Rotter
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

10.  Expression of the p53 oncogene in acute myeloblastic leukemia.

Authors:  L J Smith; E A McCulloch; S Benchimol
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

View more
  46 in total

1.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.

Authors:  G Shaulsky; N Goldfinger; A Ben-Ze'ev; V Rotter
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

3.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.

Authors:  K C Thome; A Radfar; N Rosenberg
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Authors:  D Ronen; Y Teitz; N Goldfinger; V Rotter
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

6.  Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.

Authors:  C A Felix; M M Nau; T Takahashi; T Mitsudomi; I Chiba; D G Poplack; G H Reaman; D E Cole; J J Letterio; J Whang-Peng
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

7.  A DNA binding domain is contained in the C-terminus of wild type p53 protein.

Authors:  O S Foord; P Bhattacharya; Z Reich; V Rotter
Journal:  Nucleic Acids Res       Date:  1991-10-11       Impact factor: 16.971

8.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

10.  P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.

Authors:  J Yeargin; J Cheng; A L Yu; R Gjerset; M Bogart; M Haas
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.